Search research articles
Contact Us
Filters
Showing results (21-30 of 107) with videos related to
Page
of 11
Sort By:
Future Oncology (London, England)
|
December 18, 2008
Anti-idiotypic antibody abagovomab in advanced ovarian cancer
Dirk O Bauerschlag, Christian Schem, Klaus Baumann, et al.
Women'S Health (London, England)
|
September 2, 2011
Surgery for recurrent ovarian cancer
Florian Heitz, Andreas du Bois, Christian Kurzeder, et al.
Genes, Chromosomes & Cancer
|
March 12, 2014
Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer
Liang Wang, Antonia Wenners, Felix Hilpert, et al.
Gynecologic Oncology
|
April 10, 2014
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5)
Günter Emons, Grigor Gorchev, Jalid Sehouli, et al.
Gynecologic Oncology
|
March 26, 2019
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years
Thorsten Heilmann, Jacobus Pfisterer, Antje Marie Hempel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 5, 2009
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Jacobus Pfisterer, Andreas Du Bois, Eva-Katrin Bentz, et al.
Archives of Gynecology and Obstetrics
|
February 8, 2013
Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3
Yaxi Ma, Jörg Weimer, Regina Fredrik, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract
Michael Leonard Friedlander, Alan Covens, Rosalind M Glasspool, et al.
Journal of Cancer Research and Clinical Oncology
|
May 10, 2008
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects
Christoph Mundhenke, Marion Tina Weigel, Klarissa Hanja Sturner, et al.
Oncology
|
May 18, 2011
Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles
Dirk O Bauerschlag, Ole Ammerpohl, Karen Bräutigam, et al.
Page
of 11
Search research articles
Search
Showing results (21-30 of 107) with videos related to
Sort By:
Page
of 11
Future Oncology (London, England)
|
December 18, 2008
Anti-idiotypic antibody abagovomab in advanced ovarian cancer
Dirk O Bauerschlag, Christian Schem, Klaus Baumann, et al.
Women'S Health (London, England)
|
September 2, 2011
Surgery for recurrent ovarian cancer
Florian Heitz, Andreas du Bois, Christian Kurzeder, et al.
Genes, Chromosomes & Cancer
|
March 12, 2014
Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer
Liang Wang, Antonia Wenners, Felix Hilpert, et al.
Gynecologic Oncology
|
April 10, 2014
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5)
Günter Emons, Grigor Gorchev, Jalid Sehouli, et al.
Gynecologic Oncology
|
March 26, 2019
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years
Thorsten Heilmann, Jacobus Pfisterer, Antje Marie Hempel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 5, 2009
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Jacobus Pfisterer, Andreas Du Bois, Eva-Katrin Bentz, et al.
Archives of Gynecology and Obstetrics
|
February 8, 2013
Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3
Yaxi Ma, Jörg Weimer, Regina Fredrik, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract
Michael Leonard Friedlander, Alan Covens, Rosalind M Glasspool, et al.
Journal of Cancer Research and Clinical Oncology
|
May 10, 2008
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects
Christoph Mundhenke, Marion Tina Weigel, Klarissa Hanja Sturner, et al.
Oncology
|
May 18, 2011
Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles
Dirk O Bauerschlag, Ole Ammerpohl, Karen Bräutigam, et al.
Page
of 11